常山药业：那屈肝素钙注射液获白俄罗斯药品注册证书

Core Viewpoint - Changshan Pharmaceutical (300255) has received a drug registration certificate for its product, Nadroparin Calcium Injection, from the Belarusian drug regulatory authority, valid until March 13, 2030. This approval is expected to positively impact the company's expansion into overseas markets [1]. Group 1 - The drug Nadroparin Calcium Injection is primarily used for the treatment of moderate to high-risk venous thromboembolism and the prevention of venous thromboembolic diseases [1]. - The registration approval in Belarus represents a significant step for the company in terms of international market penetration [1].